WASHINGTON (dpa-AFX) - Hemispherx Biopharma Inc. (HEB) said it has granted a new U.S. Patent for the use of Ampligen as a vaccine adjuvant for use with seasonal influenza vaccine to induce an enhanced immune response against H5N1 avian influenza.
The patent describes a method using intranasal administration of Ampligen, a toll-like receptor 3 (TLR3) agonist, along with a seasonal influenza vaccine to enhance an immune response against a H5N1 avian influenza infection compared to the administration of seasonal influenza vaccine alone.
Recently, the FDA has authorized a clinical trial to evaluate the breadth of immunological protection in healthy volunteers, potentially conveyed by Ampligen.
Copyright RTT News/dpa-AFX
© 2011 AFX News